Peer-influenced content. Sources you trust. No registration required. This is HCN.

BloodPrimary Central Nervous System Lymphoma

This review summarizes the clinical presentation, workup, staging, and recent advancements in the treatment of PCNSL. Although treatment advances include the use of BTK inhibitors and immunomodulators, relapse is common and 5-year survival is 40% or lower. Thus, accurate early diagnosis and initiation of treatment is time sensitive for optimal neurologic recovery and disease control.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form